DNA vaccination strategies for anti-tumour effective gene therapy protocols

Emanuela Signori, Sandra Iurescia, Emanuela Massi, Daniela Fioretti, Pieranna Chiarella, Mariangela De Robertis, Monica Rinaldi, Giancarlo Tonon, Vito Michele Fazio

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

After more than 15 years of experimentation, DNA vaccines have become a promising perspective for tumour diseases, and animal models are widely used to study the biological features of human cancer progression and to test the efficacy of vaccination protocols. In recent years, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has revealed a number of advantages: antigen-specific DNA vaccination stimulates both cellular and humoral immune responses; multiple or multi-gene vectors encoding several antigens/determinants and immune-modulatory molecules can be delivered as single administration; DNA vaccination does not induce autoimmune disease in normal animals; DNA vaccines based on plasmid vectors can be produced and tested rapidly and economically. However, DNA vaccines have shown low immunogenicity when tested in human clinical trials, and compared with traditional vaccines, they induce weak immune responses. Therefore, the improvement of vaccine efficacy has become a critical goal in the development of effective DNA vaccination protocols for anti-tumour therapy. Several strategies are taken into account for improving the DNA vaccination efficacy, such as antigen optimisation, use of adjuvants and delivery systems like electroporation, co-expression of cytokines and co-stimulatory molecules in the same vector, different vaccination protocols. In this review we discuss how the combination of these approaches may contribute to the development of more effective DNA vaccination protocols for the therapy of lymphoma in a mouse model.

Original languageEnglish
Pages (from-to)1583-1591
Number of pages9
JournalCancer Immunology, Immunotherapy
Volume59
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Genetic Therapy
Vaccination
DNA
DNA Vaccines
Neoplasms
Neoplasm Antigens
Antigens
Plasmids
Vaccines
Animal Disease Models
Electroporation
Humoral Immunity
Cellular Immunity
Autoimmune Diseases
Immunization
Lymphoma
Clinical Trials
Cytokines
Therapeutics
Genes

Keywords

  • B cell lymphoma
  • Cancer vaccine
  • DNA vaccination
  • Genetic immunisation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Signori, E., Iurescia, S., Massi, E., Fioretti, D., Chiarella, P., De Robertis, M., ... Fazio, V. M. (2010). DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunology, Immunotherapy, 59(10), 1583-1591. https://doi.org/10.1007/s00262-010-0853-x

DNA vaccination strategies for anti-tumour effective gene therapy protocols. / Signori, Emanuela; Iurescia, Sandra; Massi, Emanuela; Fioretti, Daniela; Chiarella, Pieranna; De Robertis, Mariangela; Rinaldi, Monica; Tonon, Giancarlo; Fazio, Vito Michele.

In: Cancer Immunology, Immunotherapy, Vol. 59, No. 10, 10.2010, p. 1583-1591.

Research output: Contribution to journalArticle

Signori, E, Iurescia, S, Massi, E, Fioretti, D, Chiarella, P, De Robertis, M, Rinaldi, M, Tonon, G & Fazio, VM 2010, 'DNA vaccination strategies for anti-tumour effective gene therapy protocols', Cancer Immunology, Immunotherapy, vol. 59, no. 10, pp. 1583-1591. https://doi.org/10.1007/s00262-010-0853-x
Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunology, Immunotherapy. 2010 Oct;59(10):1583-1591. https://doi.org/10.1007/s00262-010-0853-x
Signori, Emanuela ; Iurescia, Sandra ; Massi, Emanuela ; Fioretti, Daniela ; Chiarella, Pieranna ; De Robertis, Mariangela ; Rinaldi, Monica ; Tonon, Giancarlo ; Fazio, Vito Michele. / DNA vaccination strategies for anti-tumour effective gene therapy protocols. In: Cancer Immunology, Immunotherapy. 2010 ; Vol. 59, No. 10. pp. 1583-1591.
@article{51b53a8a5b2d47dc86a50cda68c79c95,
title = "DNA vaccination strategies for anti-tumour effective gene therapy protocols",
abstract = "After more than 15 years of experimentation, DNA vaccines have become a promising perspective for tumour diseases, and animal models are widely used to study the biological features of human cancer progression and to test the efficacy of vaccination protocols. In recent years, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has revealed a number of advantages: antigen-specific DNA vaccination stimulates both cellular and humoral immune responses; multiple or multi-gene vectors encoding several antigens/determinants and immune-modulatory molecules can be delivered as single administration; DNA vaccination does not induce autoimmune disease in normal animals; DNA vaccines based on plasmid vectors can be produced and tested rapidly and economically. However, DNA vaccines have shown low immunogenicity when tested in human clinical trials, and compared with traditional vaccines, they induce weak immune responses. Therefore, the improvement of vaccine efficacy has become a critical goal in the development of effective DNA vaccination protocols for anti-tumour therapy. Several strategies are taken into account for improving the DNA vaccination efficacy, such as antigen optimisation, use of adjuvants and delivery systems like electroporation, co-expression of cytokines and co-stimulatory molecules in the same vector, different vaccination protocols. In this review we discuss how the combination of these approaches may contribute to the development of more effective DNA vaccination protocols for the therapy of lymphoma in a mouse model.",
keywords = "B cell lymphoma, Cancer vaccine, DNA vaccination, Genetic immunisation",
author = "Emanuela Signori and Sandra Iurescia and Emanuela Massi and Daniela Fioretti and Pieranna Chiarella and {De Robertis}, Mariangela and Monica Rinaldi and Giancarlo Tonon and Fazio, {Vito Michele}",
year = "2010",
month = "10",
doi = "10.1007/s00262-010-0853-x",
language = "English",
volume = "59",
pages = "1583--1591",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "10",

}

TY - JOUR

T1 - DNA vaccination strategies for anti-tumour effective gene therapy protocols

AU - Signori, Emanuela

AU - Iurescia, Sandra

AU - Massi, Emanuela

AU - Fioretti, Daniela

AU - Chiarella, Pieranna

AU - De Robertis, Mariangela

AU - Rinaldi, Monica

AU - Tonon, Giancarlo

AU - Fazio, Vito Michele

PY - 2010/10

Y1 - 2010/10

N2 - After more than 15 years of experimentation, DNA vaccines have become a promising perspective for tumour diseases, and animal models are widely used to study the biological features of human cancer progression and to test the efficacy of vaccination protocols. In recent years, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has revealed a number of advantages: antigen-specific DNA vaccination stimulates both cellular and humoral immune responses; multiple or multi-gene vectors encoding several antigens/determinants and immune-modulatory molecules can be delivered as single administration; DNA vaccination does not induce autoimmune disease in normal animals; DNA vaccines based on plasmid vectors can be produced and tested rapidly and economically. However, DNA vaccines have shown low immunogenicity when tested in human clinical trials, and compared with traditional vaccines, they induce weak immune responses. Therefore, the improvement of vaccine efficacy has become a critical goal in the development of effective DNA vaccination protocols for anti-tumour therapy. Several strategies are taken into account for improving the DNA vaccination efficacy, such as antigen optimisation, use of adjuvants and delivery systems like electroporation, co-expression of cytokines and co-stimulatory molecules in the same vector, different vaccination protocols. In this review we discuss how the combination of these approaches may contribute to the development of more effective DNA vaccination protocols for the therapy of lymphoma in a mouse model.

AB - After more than 15 years of experimentation, DNA vaccines have become a promising perspective for tumour diseases, and animal models are widely used to study the biological features of human cancer progression and to test the efficacy of vaccination protocols. In recent years, immunisation with naked plasmid DNA encoding tumour-associated antigens or tumour-specific antigens has revealed a number of advantages: antigen-specific DNA vaccination stimulates both cellular and humoral immune responses; multiple or multi-gene vectors encoding several antigens/determinants and immune-modulatory molecules can be delivered as single administration; DNA vaccination does not induce autoimmune disease in normal animals; DNA vaccines based on plasmid vectors can be produced and tested rapidly and economically. However, DNA vaccines have shown low immunogenicity when tested in human clinical trials, and compared with traditional vaccines, they induce weak immune responses. Therefore, the improvement of vaccine efficacy has become a critical goal in the development of effective DNA vaccination protocols for anti-tumour therapy. Several strategies are taken into account for improving the DNA vaccination efficacy, such as antigen optimisation, use of adjuvants and delivery systems like electroporation, co-expression of cytokines and co-stimulatory molecules in the same vector, different vaccination protocols. In this review we discuss how the combination of these approaches may contribute to the development of more effective DNA vaccination protocols for the therapy of lymphoma in a mouse model.

KW - B cell lymphoma

KW - Cancer vaccine

KW - DNA vaccination

KW - Genetic immunisation

UR - http://www.scopus.com/inward/record.url?scp=77955553809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955553809&partnerID=8YFLogxK

U2 - 10.1007/s00262-010-0853-x

DO - 10.1007/s00262-010-0853-x

M3 - Article

VL - 59

SP - 1583

EP - 1591

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 10

ER -